Marc R. Girard

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 03, 2026

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 12, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry.

Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry.

Journal: Revue neurologique

Published: December 01, 2025

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal: Journal of neurology

Published: September 16, 2025

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Journal: JAMA network open

Published: September 15, 2025

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 07, 2025

Peripheral HLA-DRhiCD141+ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis.

Peripheral HLA-DRhiCD141+ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 03, 2025

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 15, 2025

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Journal: JAMA neurology

Published: April 14, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026